Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Curr Opin Crit Care. 2021 Aug 1;27(4):454–459. doi: 10.1097/MCC.0000000000000838

Table 1.

Hemodynamic Characteristics of the SCAI Classification of Cardiogenic Shock*

Stage Physical Examination Biochemical markers Hemodynamics
A. At Risk Normal CVP, no rales, warm, good peripheral pulses, normal mentation Normal labs, lactate and renal function SBP >100 or normal for pt. If done: CI ≥2.5, CVP <10, SvO2 >65%
B. Beginning CS ↑CVP, rales, good peripheral pulses, normal mentation Minimal renal functional impairment, elevated BNP SBP <90 or MAP <60 or >30 decrease, HR ≥100. If done: CI ≥2.2, SvO2 ≥65%
C. Classic CS May include any: Looks unwell, panicked, ashen, volume overload, rales, Killip class 3–4, cold/clammy, altered MS, decreased UO May include any: Lactate>2, doubling creatinine or 50% drop in GFR, Increased LFTs, elevated BNP May include any: SBP <90, MAP <60 or >30 decrease, and drugs/device used to maintain BP above target, CI <2.2, Ppao >15, CVP/Ppao ≥0.8, PAPI <1.85, CPO ≤0.6
D. Deteriorating/Doom Any of Stage C Any of Stage C and deteriorating Any of Stage C and require multiple pressors, mechanical circulatory support to maintain flow
E. Extremis Near pulselessness, cardiac collapse, mechanical ventilation, defibrillator used “Trying to die” pH ≤7.2, lactate ≥5 No SBP without resuscitation, pulseless electrical activity, refractory VT/VF, hypotension despite maximal support
*

Abbreviations: Brain natriuretic peptide: BNP, cardiac index: CI, cardiac power output: CPO, cardiogenic shock: CS, central venous pressure: CVP, glomerular filtration rate: GFR, liver function tests: LFTs, mean arterial pressure: MAP, mental status: MS, mixed venous O2 saturation: SvO2, pulmonary arterial occlusion pressure: Ppao, pulmonary artery pulsatility index: PAPI, patient: pt, systolic blood pressure: SBP, urine output: UO, ventricular tachycardia/fibrillation: VT/VF. Modified from reference 2. Baran et al. Catheter Cardiovasc Interv 2019;94:29-37.